Investigadors
-
Domenico Sabia
Enfocament multidisciplinari del tractament del càncer
-
Lana Bijelic
Enfocament multidisciplinari del tractament del càncer
-
Luis Ortiz De Zarate
Enfocament multidisciplinari del tractament del càncer
-
Mª Àngeles Cañas
Enfocament multidisciplinari del tractament del càncer
-
Mª Isabel Ramos Bernadó
Enfocament multidisciplinari del tractament del càncer
-
Maria Alejo
Enfocament multidisciplinari del tractament del càncer
Phd -
Maria Alejo
Enfocament multidisciplinari del tractament del càncer
-
Oriol Crusellas
Enfocament multidisciplinari del tractament del càncer
-
Pedro Barrios
Enfocament multidisciplinari del tractament del càncer
Phd -
Victor Fumanal Orús
Enfocament multidisciplinari del tractament del càncer
Contacteu amb el grup
Formulari-
Guimerà N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, Hernandez-Suarez G, Bravo IG, Molijn A, Jenkins D, Cubilla A, Muñoz N, de Sanjose S, Bosch FX, Quint W; RIS HPV TTHPV VVAPO study groups. 1127
The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study.
Am J Surg Pathol. 2013;37(9):1299-310.
-
Ndiaye C, Alemany L, Diop Y, Ndiaye N, Diémé MJ, Tous S, Klaustermeier JE, Alejo M, Castellsagué X, Bosch FX, Trottier H, Sanjosé Sd. 1129
The role of human papillomavirus in head and neck cancer in Senegal.
Infect Agent Cancer. 2013;17;8(1):14.
- Multidisciplinary treatment of peritoneal carcinomatosis in gynecological and gastrointestinal tumors
- Sugarbaker technique : radical surgery followed by peritoneal chemohyperthermia (CR + HIPEC )
- Prognostic factors of advanced ovarian epithelial carcinoma (FIGO III IV) in patients treated with extended pelviperitonectomy
- Prediction of colorectal cancer recurrence risk by immunohistochemical determination of tissue prognostic factors
- Quality of life analysis in treated and untreated patients
- Participation in national and international clinical trials for the use and validation of new drugs in the treatment of cancer
